<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Nevirapine</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Nevirapine (Viramune)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Amprenavir<sup><a href="#60">60</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">May decrease amprenavir levels</td><td valign="top">-</td><td valign="top">Decreased amprenavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Artemether<sup><a href="#593">593</a></sup><div>(Coartem)</div></td><td valign="top">artemether/lumefantrine 80/480 mg</td><td valign="top">-</td><td valign="top">Artemether AUC: decreased 72%; Cmax: decreased 61%; Lumefantrine AUC: decreased 21%; Cmax: decreased 30%</td><td valign="top">Nevirapine AUC: decreased 46%; Cmax: decreased 42%</td><td valign="top">Potentially increased treatment failure</td><td valign="top">-</td><td valign="top"><p>Do not coadminister; avoid arthemether/lumefantrine in patients receiving nevirapine if at all possible</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup/><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg atazanavir QD with 100 mg ritonavir QD</td><td valign="top">200 mg BID</td><td valign="top">Atazanavir AUC: decreased 42%; Cmax: decreased 28%; Cmin: decreased 72%</td><td valign="top">Nevirapine AUC: increased 25%; Cmax: increased 17%; Cmin: increased 32%</td><td valign="top">Decreased atazanavir effects</td><td valign="top">Induction of CYP4450 3A4 by nevirapine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup/><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg atazanavir QD with 100 mg ritonavir QD</td><td valign="top">200 mg BID</td><td valign="top">Atazanavir AUC: decreased 19%; Cmax: no significant change; Cmin: decreased 59%</td><td valign="top">Nevirapine AUC: increased 26%; Cmax: increased 21%; Cmin: increased 35%</td><td valign="top">Decreased atazanavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Chlorpropamide<sup><a href="#469">469</a></sup><div>(others)(Diabinese)</div></td><td valign="top">250 mg x 1</td><td valign="top">200 mg x 1</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>-</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Cimetidine<sup><a href="#95">95</a></sup><div>(Tagamet)(Tagamet)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Cmin: increased 21%</td><td valign="top">-</td><td valign="top">Inhibition of CYP450 3A4 by cimetidine</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Clarithromycin<sup><a href="#362">362</a>, <a href="#95">95</a></sup><div>(Biaxin)</div></td><td valign="top">500 mg BID</td><td valign="top">200 mg QD x 2 weeks then 200 BID</td><td valign="top">Clarithromycin AUC: decreased 29%; Cmax: decreased 20%; Cmin: decreased 46%; 14-hydroxy clarithromycin AUC: increased 27%</td><td valign="top">Nevirapine Cmin: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Darunavir<sup><a href="#537">537</a>, <a href="#161">161</a></sup><div>(DRV)(Prezista)</div></td><td valign="top">400 mg BID with ritonavir 100 mg BID</td><td valign="top">200 mg BID</td><td valign="top">Darunavir AUC: increased 24%; Cmax: increased 40%</td><td valign="top">Nevirapine AUC: increased 27%; Cmax: increased 18%; Cmin: increased 47%</td><td valign="top">Possibly increased darunavir effects; possibly increased nevirapine effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir<sup><a href="#727">727</a></sup><div>(Viekira)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential decrease in HCV agent efficacy</td><td valign="top">CYP3A4 induction by nevirapine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#95">95</a></sup><div>(ddI)(Videx)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#143">143</a></sup><div>(ddI)(Videx)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Dolutegravir<sup><a href="#691">691</a></sup><div>(Tivicay)</div></td><td valign="top">50 mg QD</td><td valign="top">200 mg QD; 200 mg BID; 400 mg QD (XR formulation)</td><td valign="top">Dolutegravir AUC: decreased 19%; Cmin: decreased 34%</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Efavirenz<sup><a href="#93">93</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">600 mg QD</td><td valign="top">200 mg QD x 2 weeks, then 400 mg QD</td><td valign="top">Efavirenz AUC: decreased 22%; Cmin: decreased 36%</td><td valign="top">No significant change</td><td valign="top">Decreased efavirenz effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg QD</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Elbasvir/grazoprevir<sup><a href="#733">733</a>, <a href="#727">727</a></sup><div>(Zepatier)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Decreased elbasvir, grazoprevir levels expected</td><td valign="top">Expected CYP3A4 induction by nevirapine</td><td valign="top"><p>Contraindicated: do not coadminister.  Minimal or no data to guide interaction. Risks likely to outweigh benefits. </p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Elvitegravir/cobicistat<sup><a href="#639">639</a></sup><div>(Stribild)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potentially decreased or increased elvitegravir, cobicistat and/or nevirapine effects</td><td valign="top">-</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ergotamine<sup><a href="#577">577</a></sup><div>(Cafergot, Ergot derivatives)(Cafergot, others)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Ergotamine levels may be decreased</td><td valign="top">Potential induction of CYP450 3A by nevirapine</td><td valign="top"><p>Use with caution</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ethinyl estradiol/norethindrone acetate<sup><a href="#370">370</a></sup><div>(others)(Ortho-Novum)</div></td><td valign="top">Ethinyl estradiol 0.035 mg/Norethindrone 1 mg QD x 30 days</td><td valign="top">200 mg BID x 30 days</td><td valign="top">Ethinyl estradiol: AUC decreased 23%; half-life: decreased 44%; Norethindrone: AUC decreased 18%; half-life: decreased 15%</td><td valign="top">No significant change</td><td valign="top">Possible contraceptive failure</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Avoid coadministration; additional contraceptive measures may be needed</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ethinyl estradiol/norethindrone acetate<sup><a href="#369">369</a>, <a href="#95">95</a></sup><div>(others)(Ortho-Novum)</div></td><td valign="top">Ethinyl estradiol 0.035 mg/Norethindrone 1 mg x  1 dose</td><td valign="top">200 mg QD x 2 weeks then 200 mg BID</td><td valign="top">Ethinyl estradiol AUC: decreased 19%; Cmax: no significant changeNorethindrone AUC: decreased 18%</td><td valign="top">No significant change</td><td valign="top">Possible contraceptive failure</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Use alternative contraceptive method</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Barrier devices; Condoms</b></p></td></tr><tr><td valign="top" width="10%">Etravirine<sup><a href="#407">407</a></sup><div>(ETR)(Intelence)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Etravirine AUC: decreased 55%</td><td valign="top">-</td><td valign="top">Decreased etravirine and nevirapine effects</td><td valign="top">- </td><td valign="top"><p>- </p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fluconazole<sup><a href="#269">269</a></sup><div>(Diflucan)(Diflucan)</div></td><td valign="top">200 mg QD x 40 days</td><td valign="top">200 mg QD x 14 days then 200 mg BID</td><td valign="top">No significant change</td><td valign="top">Nevirapine AUC: increased 110%; Cmax: increased 115%; Cmin: increased 135%; half-live: decreased 52% (data compared to historical controls)</td><td valign="top">Increased nevirapine effects</td><td valign="top">Possible inhibition of CYP450 3A4 by fluconazole</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Fluconazole<sup><a href="#427">427</a></sup><div>(Diflucan)(Diflucan)</div></td><td valign="top">200 mg three times weekly</td><td valign="top">200 mg BID</td><td valign="top">- </td><td valign="top">Nevirapine AUC: increased 33%; Cmin: increased 38%; Cmax: increased 26%</td><td valign="top">Possibly increased nevirapine effects</td><td valign="top">Inhibition of CYP450 3A4 by fluconazole</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fosamprenavir<sup><a href="#146">146</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">1400 mg BID</td><td valign="top">200 mg BID</td><td valign="top">Fosamprenavir AUC: decreased 33%; Cmax: decreased 25%; Cmin: decreased 35%</td><td valign="top">Nevirapine AUC: increased 29%; Cmax: increased 25%; Cmin: increased 34%</td><td valign="top">Decreased fosamprenavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Consider ritonavir-boosted fosamprenavir</b></p></td></tr><tr><td valign="top" width="10%">Fosamprenavir<sup><a href="#146">146</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">700 mg fosamprenavir BID with 100 mg ritonavir BID</td><td valign="top">200 mg BID</td><td valign="top">No significant change</td><td valign="top">Nevirapine Cmin: increased 22%</td><td valign="top">-</td><td valign="top">Induction of CYP450 3A4 by nevirapine; inhibition of CYP450 3A4 by ritonavir</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#254">254</a>, <a href="#29">29</a>, <a href="#30">30</a>, <a href="#31">31</a>, <a href="#32">32</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg Q8H</td><td valign="top">200 mg BID</td><td valign="top">Indinavir AUC: decreased 28%; Cmax: decreased 11%</td><td valign="top">No significant change</td><td valign="top">Decreased indinavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Increase indinavir to 1000 mg Q8H</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#95">95</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg Q8H</td><td valign="top">200 mg QD x 2 weeks, 200 mg BID x 28 days</td><td valign="top">Indinavir AUC: decreased 28%; Cmax: no significant change</td><td valign="top">Not studied</td><td valign="top">Decreased indinavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Increase indinavir to 1000 mg Q8H</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ketoconazole<sup><a href="#95">95</a></sup><div>(Nizoral)</div></td><td valign="top">400 mg QD x 2 weeks</td><td valign="top">200 mg QD x 2 weeks then 200 mg BID x 2 weeks</td><td valign="top">Ketoconazole AUC: decreased 63%; Cmax: decreased 40%</td><td valign="top">Levels: increased 15-30%</td><td valign="top">Decreased ketoconazole effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">300 mg/75 mg/square meter BID x 3 weeks</td><td valign="top">7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week</td><td valign="top">Lopinavir AUC: decreased 22%; Cmax: no significant change; Cmin: decreased 55%</td><td valign="top">-</td><td valign="top">Decreased lopinavir/ritonavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Increase dose of lopinavir/ritonavir to 6.5 mL BID with food</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">400 mg/100 mg BID x 20 days</td><td valign="top">200 mg QD x 14 days, 200 mg BID x 6 days</td><td valign="top">Lopinavir: no significant change</td><td valign="top">Nevirapine AUC: no significant change; Cmax: no significant change; Cmin: increased 15%</td><td valign="top">Though study does not suggest need to increase lopinavir/ritonavir dose, other evidence indicated decreased lopinavir/ritonavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Increase dose of lopinavir/ritonavir to 533 mg/133 mg (4 capsules) BID with food</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lumefantrine<sup><a href="#455">455</a></sup><div>(Coartem)</div></td><td valign="top">Artemether/lumefantrine 80 mg/480 mg x 6 doses</td><td valign="top">200 mg BID</td><td valign="top">Lumefantrine AUC: increased 56%; Cmax: increased 24%; half-life: no significant change; clearance: decreased 36%</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">Unknown</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Lumefantrine<sup><a href="#593">593</a></sup><div>(Coartem)</div></td><td valign="top">artemether/lumefantrine 80/480 mg</td><td valign="top">-</td><td valign="top">Lumefantrine AUC: decreased 21%; Cmax: decreased 30%</td><td valign="top">Nevirapine AUC: decreased 46%; Cmax: decreased 42%</td><td valign="top">Potentially increased treatment failure</td><td valign="top">-</td><td valign="top"><p>Do not coadminister; avoid arthemether/lumefantrine in patients receiving nevirapine if at all possible</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Maraviroc<sup><a href="#2">2</a></sup><div>(MVC)(Selzentry)</div></td><td valign="top">300 mg</td><td valign="top">200 mg BID</td><td valign="top">Maraviroc Cmax: increased 54%</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Increase maraviroc dose to 300 mg BID</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Medroxyprogesterone acetate<sup><a href="#393">393</a></sup><div>(Depo-Provera)</div></td><td valign="top">150 mg</td><td valign="top">-</td><td valign="top">Progesterone levels: no significant change</td><td valign="top">Nevirapine AUC: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#186">186</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">stable dose</td><td valign="top">unknown</td><td valign="top">Not reported</td><td valign="top">Nevirapine AUC: decreased 40%</td><td valign="top">Decreased methadone effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#183">183</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">stable dose: racemic methadone 35-220 mg daily; (R)-methadone 45-115 mg daily</td><td valign="top">200 mg QD x 14 days, then 200 mg BID thereafter</td><td valign="top">racemic methadone AUC: decreased 37%; (R)-methadone AUC: decreased 44%</td><td valign="top">-</td><td valign="top">Decreased methadone effects (eg, withdrawal)</td><td valign="top">Possible induction of CYP450 2B6 by nevirapine</td><td valign="top"><p>Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#210">210</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">Stable methadone dose</td><td valign="top">200 mg QD x 14 days</td><td valign="top">Methadone AUC: decreased 51%; Cmax: decreased 36%</td><td valign="top">Not studied</td><td valign="top">Decreased methadone effects (eg, methadone withdrawal)</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#207">207</a>, <a href="#208">208</a>, <a href="#209">209</a>, <a href="#95">95</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">Stable methadone maintenance</td><td valign="top">200-400 mg QD</td><td valign="top">Methadone AUC: decreased 46%</td><td valign="top">Not studied</td><td valign="top">Decreased methadone effects (eg, methadone withdrawal; interaction observed one week into therapy</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Mycophenolate<sup><a href="#312">312</a></sup><div>(CellCept)(CellCept)</div></td><td valign="top">500 mg BID x 8 weeks</td><td valign="top">200 mg BID</td><td valign="top">Not studied</td><td valign="top">Clearance: increased 27%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nelfinavir<sup><a href="#24">24</a>, <a href="#73">73</a>, <a href="#74">74</a></sup><div>(NFV)(Viracept)</div></td><td valign="top">750 mg TID x 36 days</td><td valign="top">200 mg QD x 14 days, 200 mg BID x 14 days</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Paclitaxel<sup><a href="#174">174</a></sup><div>(Taxol)</div></td><td valign="top">100 mg/square meter infusion over 3 hours</td><td valign="top">200 mg BID</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifabutin<sup><a href="#95">95</a></sup><div>(Mycobutin)(Mycobutin)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">Nevirapine Cmin: decreased 16%</td><td valign="top">Decreased nevirapine effects</td><td valign="top">Induction of CYP450 3A4 by rifabutin</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Rifampin<sup><a href="#95">95</a>, <a href="#351">351</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">Nevirapine Cmin: decreased 37%</td><td valign="top">Decreased nevirapine effects</td><td valign="top">Induction of CYP450 3A4 by rifampin</td><td valign="top"><p>Avoid if possible</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#347">347</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">450 mg if &amp;lt; 55 kg and 600 mg if &amp;gt; 55 kg x 7 days</td><td valign="top">200 mg x 1</td><td valign="top">-</td><td valign="top">Nevirapine AUC: decreased 79%; Cmax: decreased 20%; Cmin: decreased 60%; half-life: decreased 66%</td><td valign="top">Decreased nevirapine effects</td><td valign="top">Induction of CYP450 3A4 by rifampin</td><td valign="top"><p>Do not coadminister</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr><td valign="top" width="10%">Rifampin<div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">200 mg BID</td><td valign="top">-</td><td valign="top">Nevirapine AUC: decreased 27% (at week 4); Nevirapine AUC: no significant change (at week 10)Nevirapine AUC with rifampicin approximates nevirapine baseline without rifampicin at week 10.</td><td valign="top">Decreased nevirapine effects</td><td valign="top">-</td><td valign="top"><p>Regimen most appropriate for countries where rifabutin is not available; Avoid nevirapine and rifampicin/rifampin if rifabutin is available (rifabutin preferred agent)</p><p class="warn"><i>Alternative Agents</i>: <br/><b> Rifabutin</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#356">356</a>, <a href="#351">351</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD</td><td valign="top">200 mg BID</td><td valign="top">No significant change</td><td valign="top">Nevirapine AUC: decreased 31%; Cmax: decreased 36%; Cmin: decreased 21%</td><td valign="top">Decreased nevirapine effects</td><td valign="top">Induction of CYP450 3A4 by rifampin</td><td valign="top"><p>Avoid if possible</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Rifabutin</b></p></td></tr><tr><td valign="top" width="10%">Ritonavir<sup><a href="#95">95</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">600 mg BID</td><td valign="top">200 mg QD x 2 weeks then 200 mg BID x 28 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Saquinavir<sup><a href="#95">95</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">600 mg (hard gel caps) TID</td><td valign="top">200 mg QD x 2 weeks then 200 mg BID x 28 days</td><td valign="top">Saquinavir AUC: decreased 24%; Cmax: decreased 28%</td><td valign="top">No significant change</td><td valign="top">Decreased saquinavir effects</td><td valign="top">Induction of CYP450 3A4 by nevirapine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Saquinavir<sup><a href="#44">44</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">600 mg (hard gel caps) TID x 7 days</td><td valign="top">200 mg BID x 21 days</td><td valign="top">Saquinavir AUC: decreased 24%; Cmax: decreased 28%</td><td valign="top">No significant change</td><td valign="top">May decrease saquinavir effects</td><td valign="top">Induction of CYP450 by nevirapine</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Nevirapine</th><th>Effect on Drug Levels</th><th>Effect on Nevirapine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">St. John's Wort<sup><a href="#174">174</a></sup><div>(Hypericum perforatum, hypericin, hyperforin)</div></td><td valign="top">- </td><td valign="top">200 mg BID</td><td valign="top">- </td><td valign="top">Clearance: increased 35%</td><td valign="top">Decreased nevirapine effects</td><td valign="top">Induction of CYP450 3A4 by St. John's Wort</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#143">143</a></sup><div>(TDF)(Viread)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">1250 mg BID with 100 mg ritonavir BID x 42 doses</td><td valign="top">200 mg BID x 43 doses</td><td valign="top">-</td><td valign="top">Nevirapine AUC: decreased 24%; Cmax: decreased 29%; Cmin: decreased 23%</td><td valign="top">Possible decreased nevirapine effects</td><td valign="top">Possible induction of CYP450 3A4 by tipranavir/ritonavir</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">250 mg BID with 200 mg ritonavir BID</td><td valign="top">200 mg BID x 43 doses</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">750 mg BID with 100 mg ritonavir BID</td><td valign="top">200 mg BID x 43 doses</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Warfarin<sup><a href="#95">95</a></sup><div>(Coumadin)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Possibly decreased warfarin effects (eg, altered INR, increased risk of clotting)</td><td valign="top">-</td><td valign="top"><p>Monitor INR and adjust warfarin as indicated</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Zalcitabine<sup><a href="#95">95</a></sup><div>(ddC)(Hivid)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Zidovudine<sup><a href="#95">95</a></sup><div>(AZT, ZDV)(Retrovir)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="2"> </a>2:</td><td class="cellleft">Selzentry [package insert]. New York, NY: Pfizer, Inc.; August 2012.</td></tr><tr><td valign="top" class="cellrightblue"><a name="24"> </a>24:</td><td class="cellleft">Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="29"> </a>29:</td><td class="cellleft">Viramune [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 1998.</td></tr><tr><td valign="top" class="cellrightblue"><a name="30"> </a>30:</td><td class="cellleft">Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis. 1998;177:1514-20.</td></tr><tr><td valign="top" class="cellrightblue"><a name="31"> </a>31:</td><td class="cellleft">Murphy RL, Sommadossi J, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179:1116-23.</td></tr><tr><td valign="top" class="cellrightblue"><a name="32"> </a>32:</td><td class="cellleft">Launay O, Peytavin G, Flandre P, et al. Pharmacokinetic (PK) interaction between nevirapine (NVP) and indinavir (IDV) in ANRS 081 trial. [abstract #1632]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="44"> </a>44:</td><td class="cellleft">Fortovase [package insert]. Basel, Switzerland: F. Hoffman-La Roche Ltd.;2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="60"> </a>60:</td><td class="cellleft">Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="73"> </a>73:</td><td class="cellleft">Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine.  Aids 1998;12(10):1243-44.</td></tr><tr><td valign="top" class="cellrightblue"><a name="74"> </a>74:</td><td class="cellleft">Vilaro J, Mascaro J, Colomer J, et al. The pharmacokinetics of combination therapy with nelfinavir (NFV) plus neviarapine (NVP) in HIV positive patients [abstract #A-497]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="78"> </a>78:</td><td class="cellleft">Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="93"> </a>93:</td><td class="cellleft">Veldkamp AI, Hoetelmans RMW, Beijnen JH, et al. DONUT: The pharmacokinetics (PK) of once daily nevirapine (NVP) and efavirenz (EFV) when used in combination [abstract #80]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 January 30th-February 2; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="95"> </a>95:</td><td class="cellleft">Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="143"> </a>143:</td><td class="cellleft">Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="146"> </a>146:</td><td class="cellleft">DeJesus E, Piliero P, Summers K, et al. Evaluation of the pharmacokinetic drug interaction between fosamprenavir, fosamprenavir plus ritonavir and nevirapine in HIV-infected patients [abstract A-447]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C.</td></tr><tr><td valign="top" class="cellrightblue"><a name="154"> </a>154:</td><td class="cellleft">Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="161"> </a>161:</td><td class="cellleft">Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010.</td></tr><tr><td valign="top" class="cellrightblue"><a name="174"> </a>174:</td><td class="cellleft">de Maat MMR, Mathot RAA, Hoetelmans RMW, et al. A population pharmacokinetic model of nevirapine reveals drug interaction with St. John's wort in a cohort of HIV-1-infected patients [abstract #1.2]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 April 2-4; Noordwijk, the Netherlands.</td></tr><tr><td valign="top" class="cellrightblue"><a name="183"> </a>183:</td><td class="cellleft">Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficicency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 4148-53.</td></tr><tr><td valign="top" class="cellrightblue"><a name="186"> </a>186:</td><td class="cellleft">Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces methadone levels in IV-infected patients [abst 867]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France.</td></tr><tr><td valign="top" class="cellrightblue"><a name="207"> </a>207:</td><td class="cellleft">Altice FL, Cooney E, Friedland GH.  Nevirapine induced methadone withdrawal: Implications for antiretroviral treatment of opiate dependent HIV infected patients [abstract #372]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="208"> </a>208:</td><td class="cellleft">Heelon MW, Meade LB.  Methadone withdrawal when starting an antiretroviral regimen including nevirapine.  Pharmacotherapy 1999;19:471-72.</td></tr><tr><td valign="top" class="cellrightblue"><a name="209"> </a>209:</td><td class="cellleft">Clarke S, Mulcahy F, Back D, et al.  Managing methadone and non-nucleoside reverse transcriptase inhibitors: Guidelines for clinical practice [abstract #88]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="210"> </a>210:</td><td class="cellleft">Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-7.</td></tr><tr><td valign="top" class="cellrightblue"><a name="254"> </a>254:</td><td class="cellleft">CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Jan 28, 2000. [AIDS Treatment Information Service: Current Treatment] Available at: http://www.hivatis.org/trtgdlns.html.</td></tr><tr><td valign="top" class="cellrightblue"><a name="269"> </a>269:</td><td class="cellleft">Orrell CJ, Geel J, Pitt JA, et al. Effect of fluconazole on nevirapine pharmacokinetics [abstract TuPeB4606]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand.</td></tr><tr><td valign="top" class="cellrightblue"><a name="312"> </a>312:</td><td class="cellleft">Sankatsing S, Hoggard P, Back D, et al. Mycophenolate mofetil lowers plasma nevirapine concentrations but has no effect on intracellular triphospate concentrations [abstract #539]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="347"> </a>347:</td><td class="cellleft">Pujari S, Bele V, Joshi K, et al. Effect of rifampicin hepatic induction on nevirapine concentrations in Indian volunteers [abst # 574]. 13th Conference on Retrovirus and Opportunistic Infections; 2006 Feb 5-8; Denver, Colorado.</td></tr><tr><td valign="top" class="cellrightblue"><a name="351"> </a>351:</td><td class="cellleft">Centers for Disease Control and Prevention. Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. Updated January 20, 2004.  www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm.</td></tr><tr><td valign="top" class="cellrightblue"><a name="356"> </a>356:</td><td class="cellleft">Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acq Imm Defic Syn 2001;28:450-3.</td></tr><tr><td valign="top" class="cellrightblue"><a name="362"> </a>362:</td><td class="cellleft">Robinson P, Gigliotti M, Lamson M, et al.  Effect of reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients [abstract #374]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 30-Feb 2; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="369"> </a>369:</td><td class="cellleft">Leitz G, Mildvan D, McDonough M, et al.  Nevirapine (Viramune) and ethinyl estradiol/noethindrone [Ortho-Novum 1/35 (21 pack) EE/NET] interaction study in HIV-1 infected-women [abstract #89]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 31-Feb 4; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="370"> </a>370:</td><td class="cellleft">Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradil/norethindrone when adminstered concurrently to HIV-infected women. J Acq Immune Def Syn 2002;29:471-7.</td></tr><tr><td valign="top" class="cellrightblue"><a name="393"> </a>393:</td><td class="cellleft">Cohn SE, Watts D, Lertora J, et al. An open-label, non-randomized study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women [abst. #82} 12th Conference on Retroviruses and Opportunistic Infections; 2005 February 22-25; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="407"> </a>407:</td><td class="cellleft">Baede P, Piscitelli S, Graham N, et al. Drug Interactions with TMC125, a Potent Next Generation NNRTI. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract A-1827.</td></tr><tr><td valign="top" class="cellrightblue"><a name="427"> </a>427:</td><td class="cellleft">Wakeham K, Ggay AB, Watson V, et al. Coadministration of fluconazole increases nevirapine concentrations in HIV-infected ugandans [poster 700]. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="455"> </a>455:</td><td class="cellleft">Kredo T, Van der Walt JS, Mauff K, et al. Nevirapine increases lumefantrine exposure in HIV-infected subjects [abstract 603]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-18; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="469"> </a>469:</td><td class="cellleft">Bakare-Odunola MT, Enemaili I, Garba M, et al. The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Eur J Drug Metab Pharmacokinet 2008; 33: 165-71.</td></tr><tr><td valign="top" class="cellrightblue"><a name="537"> </a>537:</td><td class="cellleft">Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1 infected patients. Brit J Clin Pharmacol 2009; 68: 116-19.</td></tr><tr><td valign="top" class="cellrightblue"><a name="577"> </a>577:</td><td class="cellleft">Viramune [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 2011.</td></tr><tr><td valign="top" class="cellrightblue"><a name="593"> </a>593:</td><td class="cellleft">Byakika-Kibwika P, Lamorde M, Mayanja-Kizza H, et al. Significant pharmacokinetic interaction between nevirapine and artemether-lumefantrine in HIV+ adults: Uganda [paper #614]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012. Seattle, WA.</td></tr><tr><td valign="top" class="cellrightblue"><a name="639"> </a>639:</td><td class="cellleft">DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Feb 12, 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="691"> </a>691:</td><td class="cellleft">Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; August 2015</td></tr><tr><td valign="top" class="cellrightblue"><a name="727"> </a>727:</td><td class="cellleft">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.</td></tr><tr><td valign="top" class="cellrightblue"><a name="733"> </a>733:</td><td class="cellleft">Unique Patient Populations: Patients with HIV/HCV Co-infection. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases. Available at http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>